EGFR drugs for Non-Small Cell Lung Cancer
41 tracked EGFR drugs in the Non-Small Cell Lung Cancer race. The class explanation lives on the EGFR page; the full indication pipeline across every mechanism is on the Non-Small Cell Lung Cancer page.
5 approved / phase 414 Phase 32 Phase 2/33 Phase 212 Phase 1/25 Phase 1
Head-to-head evidence: Almonertinib vs ALX2004 · ALX2004 vs Asandeutertinib · ALX2004 vs BEBT-109 · ALX2004 vs BPI-361175 · ALX2004 vs Becotatug · ALX2004 vs Befotertinib